Medicament for treatment of non-insulin dependent diabetes mellitus, hypertension and/or metabolic syndrome

Abstract

A substance including the chemical structures of bicyclo[3.2.1]octan or the chemical structures of kaurene for the use in a dietary supplementation or as a constituent in a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and / or the metabolic syndrome. The unique chemical structures of bicyclo[3.2.1]octan alone or in a kaurene structure provides the substances, such as e.g. steviol, isosteviol and stevioside with the capability of enhancing or potentiating the secretion of insulin in a plasma glucose dependent manner. The substances including these unique chemical structures also have the capability of reducing the glucagon concentration in the blood and / or lowering the blood pressure thereby providing a self-regulatory treatment system for non-insulin dependent diabetes mellitus and / or hypertension. In a combination drug which also comprise a soy protein, and / or soy fiber and / or at least one isoflavone these substances act synergistically and such combination drugs are highly useful both prophylacticly or directly in the treatment of e.g. the metabolic syndrome and obesity and has due to the self-regulatory effect a widespread applicability as a dietary supplementation.

Description

[0001] This application is a continuation of U.S. application Ser. No. 10 / 933,297 filed Sep. 3, 2004, which is a division of 10 / 210,787 filed Jul. 31, 2002, which is a continuation of PCT / DK01 / 00075 filed Feb. 1, 2001. The prior applications set forth above are hereby incorporated by reference in their entirety.TECHNICAL FIELD [0002] The present invention relates to a new medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension, metabolic syndromes and other conditions in mammals. BACKGROUND ART [0003] Diabetes is a common disease that has a prevalence of 2-4% in the population. Non-insulin dependent diabetes mellitus comprises about 85% of diabetes most commonly occurring at the age above 40 years. The incidence of non-insulin dependent diabetes mellitus is increasing and is at a global level expected to surpass 200 million subjects at year 2010. [0004] Diabetes is associated with increased morbidity and a 2-4-fold increase in mortality primarily due to...

AI Technical Summary

Benefits of technology

The medicament effectively controls plasma glucose levels, suppresses fasting triglycerides and cholesterol, and reduces blood pressure without causing hypoglycemia, offering a safe and single-drug solution for managing NIDDM and metabolic syndrome.

Problems solved by technology

However, it will often be necessary to add pharmacological therapy but until today no single drug that simultaneously attacks hyperglycaemia, hypertension and dyslipidemia are available for patients with metabolic syndrome.

This type of treatment is difficult to adjust and administer to the patient and such treatment may result in many unwanted adverse effects which in themselves may need medical treatment.

However if such an action also affects the myocytes in the heart, an increased risk of cardiac arrhythmias might be present.

Also, it is well know in the art that sulphonylureas can cause severe and lifethreatening hypoglycemia, due to their continuous action as long as they are present in the blood.

However, total lack of data on blood glucose, insulin and / or blood pressure i.e., lack of support by test results and the missing information of which types of diabetes that were treated, makes this an unsupported and unconfirmed assertion.

Images